1-氮杂双环[2.2.1]庚烷-4-甲酰胺 | 119103-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-氮杂双环[2.2.1]庚烷-4-甲酰胺
• 英文名称: 1-azabicyclo[2.2.1]hept-4-yl carboxamide
• 英文别名: 1-Azabicyclo[2.2.1]heptane-4-carboxamide
• CAS: 119103-03-6
• 化学式: C₇H₁₂N₂O
• mdl: MFCD18806523
• 分子量: 140.185
• InChiKey: SZWZKCNJKSJNIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  301.9±21.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氮杂双环[2.2.1]庚烷-4-甲酰胺 在 吡啶 、 甲醇 、 三氟乙酸酐 作用下， 以 四氢呋喃 为溶剂， 反应 26.75h， 生成 (1S,3R,4S)-3-(1-Methyl-1H-tetrazol-5-yl)-1-aza-bicyclo[2.2.1]heptane
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007
• 作为产物：
  描述：

  1-azabicyclo[2.2.1]heptane-4-carbonyl chloride hydrochloride 在 氨 作用下， 以 二氯甲烷 为溶剂， 生成 1-氮杂双环[2.2.1]庚烷-4-甲酰胺
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007

文献信息

• Novel compounds
  申请人：Beecham Group plc

  公开号：US04971975A1

  公开（公告）日：1990-11-20

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which X represents R.sub.1 OOC-- in which R.sub.1 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl; R.sub.2 O-- in which R.sub.2 is C.sub.1-2 alkyl, C.sub.1-2 alkylcarbonyl or aminocarbonyl optionally substituted by one or two methyl groups; a group ##STR2## in which Y represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, any amino nitrogen optionally substituted by a C.sub.1-2 alkyl group, Y being optionally C-substituted by a methyl group; or a group ##STR3## in which A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.3 and the other is nitrogen or CR.sub.4 where R.sub.3 and R.sub.4 are independently selected from hydrogen and methyl; and each of p and q independently represents an integer of 2 to 4.

  化学式（I）的化合物或其药学上可接受的盐：##STR1## 其中X代表R.sub.1 OOC--，其中R.sub.1是C.sub.1-4烷基，C.sub.2-4烯基或C.sub.2-4炔基；R.sub.2 O--其中R.sub.2是C.sub.1-2烷基，C.sub.1-2烷基羰基或氨基羰基，可选择地被一个或两个甲基基团取代；一个基团##STR2## 其中Y代表一个3-成员二价残基，完成一个5-成员芳香环并包括一个或两个从氧、氮和硫中选择的杂原子，任何氨基氮可选择地被一个C.sub.1-2烷基基团取代，Y可选择地被一个甲基基团取代；或一个基团##STR3## 其中A.sub.1是氧或硫，A.sub.2和A.sub.3中的一个是CR.sub.3，另一个是氮或CR.sub.4，其中R.sub.3和R.sub.4分别独立地选择自氢和甲基；每个p和q独立地表示2到4的整数。
• 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
  申请人：Pfister Jurg R.

  公开号：US20090088418A1

  公开（公告）日：2009-04-02

  The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

  本发明涉及影响尼古丁乙酰胆碱受体（nAChRs）的化合物和配方，例如，作为特定尼古丁受体亚型（具体来说是α7 nAChR亚型）的调节剂。本发明还涉及用于治疗各种疾病和紊乱的方法，特别是与中枢和自主神经系统功能障碍相关的疾病。
• 2′ Biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR
  作者：Brian Budzik、Vincenzo Garzya、Dongchuan Shi、James J. Foley、Ralph A. Rivero、Christopher J. Langmead、Jeannette Watson、Zining Wu、Ian T. Forbes、Jian Jin

  DOI：10.1016/j.bmcl.2010.04.128

  日期：2010.6

  Biaryl amides were discovered as novel and subtype selective M1 muscarinic acetylcholine receptor agonists. The identification, synthesis, and initial structure–activity relationships that led to compounds 3j and 4c, possessing good M1 agonist potency and intrinsic activity, and subtype selectivity for M1 over M2–5, are described.

  发现联芳基酰胺是新型和亚型的选择性M 1毒蕈碱乙酰胆碱受体激动剂。描述了导致化合物3j和4c的鉴定，合成和初始结构-活性关系，它们具有良好的M 1激动剂效力和内在活性，以及​​M 1相对于M 2-5的亚型选择性。
• Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
  申请人：Beecham Group p.l.c.

  公开号：EP0402056A2

  公开（公告）日：1990-12-12

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: in which one of X and Y represents hydrogen and the other represents Z, where Z is a group in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a C1-2 alkyl, cyclopropyl or propargyl group, r represents an integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0 or 1, with the proviso that when Y is hydrogen s is 1.

  式 (I) 的化合物或其药学上可接受的盐： 其中 X 和 Y 的一个代表氢，另一个代表 Z，其中 Z 是一个基团 其中 Q 代表完成五元芳香环的三元二价残基，包含两个或三个氮原子，任何氨基氮均被 C1-2 烷基、环丙基或丙炔基取代，r 代表 2 或 3 的整数，s 代表 1 或 2 的整数，t 代表 0 或 1，但当 Y 为氢时，s 为 1。
• Bridgehead substituted azabicyclic derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0287356B1

  公开（公告）日：1996-01-24